Trials / Completed
CompletedNCT00344110
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
A Randomized, Double-blind, Placebo and Active-controlled, Multicenter, Parallel-group Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy, Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 768 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- —
Summary
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2006-06-26
- Last updated
- 2016-11-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00344110. Inclusion in this directory is not an endorsement.